# Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens

> **NCT00149214** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 257 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** pemetrexed
- **DRUG:** cyclophosphamide
- **DRUG:** doxorubicin
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT00149214
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2008-02
- **Final completion:** 2011-03
- **Target enrollment:** 257 (ACTUAL)
- **Last updated:** 2012-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00149214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00149214, "Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00149214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*